Introduction
Psychotropic drug-related weight gain (PDWG) frequently occurs with the use of psychiatric drugs, such as antipsychotics, antidepressants, lithium, and anticonvulsants. The onset of PDWG is often associated with non-concordance with treatment recommendations and dissatisfaction with psychiatric drugsReference McIntyre, Kwan, Rosenblat, Teopiz and Mansur1. Notwithstanding, the risk of weight gain with the use of psychotropic drugs varies depending on the type of drug used. For example, weight gain associated with antipsychotic use, such as clozapine and olanzapine, tends to be relatively higher compared to other psychotropic drugsReference Pillinger, McCutcheon and Vano2. For individuals experiencing PDWG, common management strategies include the discontinuation of the psychotropic drug causing weight gain and switching to an alternative drug that has a lower risk of PDWG or attempting a behavioral or pharmacologic intervention to target weight gainReference McIntyre, Kwan, Rosenblat, Teopiz and Mansur1.
PDWG is a clinically relevant issue and a priority therapeutic targetReference Liu, Ling and Lui3, Reference Jawad, Meshkat and Tabassum4, as levels of obesity and body mass index (BMI) in psychiatric populations are rising at a higher rate compared to the general populationReference Najar, Joas, Jonsson, Pålsson and Landén5–Reference Taylor, McIntyre, Remington, Levitan, Stonehocker and Sharma7. Greater levels of obesity are especially concerning, as obesity is associated with higher morbidity and mortality, impaired global functioning, overall quality of life, and potentially shortened lifespan and health span in psychiatric populationsReference McIntyre, Kwan, Rosenblat, Teopiz and Mansur1, Reference Fagiolini, Kupfer, Houck, Novick and Frank8–Reference McIntyre10.
Treatment of PDWG includes lifestyle and behavioral modifications, which are similarly effective as weight-loss intervention in psychiatric populations as compared to the general populationReference Daumit, Dickerson and Wang11. However, individuals with severe mental illness may face unique barriers to engaging in these aforementioned interventions including economic, healthcare access and availability and cognitive aspects intrinsic to mental illness affecting motivation and treatment implementation. Consequently, alternative pharmacologic interventions for the treatment and prevention of PDWG and related metabolic abnormalities are needed.Reference McIntyre, Kwan, Rosenblat, Teopiz and Mansur1, Reference Allison, Mentore and Heo12
Glucagon-like peptide-1 (GLP-1) is a peptide hormone produced by the intestine in response to meal ingestion, which stimulates the secretion of insulin, decreases gastric emptying and inhibits food intakeReference Hira, Pinyo and Hara13, Reference Müller, Finan and Bloom14. GLP-1 receptor agonists (GLP-1RAs) mimic the functions of endogenous GLP-1, having beneficial effects on metabolic regulation and allowing for weight lossReference Vilsboll, Christensen, Junker, Knop and Gluud15. As a result, GLP-1RAs, such as exenatide and semaglutide are commonly administered as a treatment for obesity in type 2 diabetes mellitus (T2DM) and polycystic ovary syndromeReference Wang, Wang and Yang16. Similarly, GLP-1RAs have been used to treat PDWGReference Ishøy, Knop and Broberg17–Reference Whicher, Price and Phiri22. In this systematic review, we aim to synthesize extant evidence from randomized controlled trials (RCTs) on the use of GLP-1RAs to mitigate PDWG.
Methods
Search and selection strategy
A systematic search was conducted on online databases, including PubMed, OVID Medline, and Google Scholar, from inception until January 1, 2024. Subsequent manual searches of the reference lists of any relevant articles were conducted. The databases PubMed, and OVID Medline were searched using the following Boolean search string: ((“depression” OR “schizophrenia” OR “bipolar disorder”) AND (“weight gain”) AND (“antipsychotic*” OR “psycho* drug”) AND (“GLP-1”)). A second search string was used to search for the efficacy of Food and Drug Administration (FDA)-approved GLP-1 agonists against the topic of interest in RCTs: ((“psycho* drug”) AND (“weight gain” OR “weight loss”) AND (“GLP-1” OR “glucagon-like peptide-1” OR “exenatide” OR “liraglutide” OR “dulaglutide” OR “lixisenatide” OR “insulin degludec” OR “insulin glargine” OR “semaglutide” OR “tirzepatide” AND “randomized controlled trial”)). Studies were limited to the language of publication (ie, English).
Three reviewers (SL, XYG, and TM) independently screened articles using the Covidence platform. After removing duplicated articles, identified studies were screened by titles, abstracts, and full-text against eligibility criteria. Any conflicts regarding article screening between reviewers were resolved through discussion.
Eligibility criteria
Eligible studies had enrolled participants who had previously or currently been prescribed a psychotropic drug (ie, antidepressants, antipsychotics) and experienced drug-related weight gain. The eligible population was limited to adults aged ≥18 who were clinically diagnosed as overweight/obese. Additionally, only studies developed as RCTs with GLP-1RA intervention groups and placebo-controlled groups were considered.
Studies were excluded if they: (i) were secondary research (eg, systematic reviews, meta-analyses of RCTs, narrative reviews, commentaries, etc.), (ii) were animal studies, and (iii) were not written in English.
Data extraction process
Extracted data were established a priori using a piloted data extraction table. Data extraction was conducted by three independent reviewers (TM, SL, and XYG). The extracted data included: i) authors and publication year, ii) study design, iii) sample size, iv) participant eligibility criteria, v) treatment allocation, vi) study duration, vii) treatment outcomes, and viii) significance operationalized by p-values indicating relationships between the control and experimental groups, where a p-value <.05 was considered significant in yielding weight loss benefits by GLP-1RAs. For papers that did not report a final p-value, the primary outcome measure defined by the authors was obtained.
Study of risk of bias assessment
Study quality was assessed by three independent reviewers (SL, XYG, and TM) using Cochrane’s revised risk-of-bias tool for randomized trials (Table 1)Reference Sterne, Savovic and Page23. Each paper was assessed at least twice by two different reviewers.
Table 1. Risk of Bias Assessment
The signaling questions in Table 10 of the risk-of-bias tool approached the potential biases of each selected study: bias due to outcome measurement, bias between intervention groups, bias from non-blind study design, bias due to knowledge of the intervention, and bias in outcome due to perceived knowledgeReference Sterne, Savovic and Page23.
Results
Study results and selection
The initial search generated 8945 publications from PubMed and OVID Medline databases, as seen on the PRISMA Flowchart (Figure 1). After removing study duplicates, 4566 papers remained for title and abstract screening, of which 70 were deemed eligible for full-text screening. From full-text screening, six eligible publications were included in the systematic review, the majority being excluded due to study design or wrong outcome (ie, the study’s final outcome was irrelevant to the research question).
Figure 1. PRISMA Flow Diagram
Synthesis
A summary of the characteristics and results of the six included RCTs is displayed in Table 2 and Table 3. All participants undergoing treatment were either obese, prediabetic, or diagnosed with diabetes mellitus (DM). Additionally, the participants were either diagnosed with a schizophrenia spectrum disorder or bipolar disorder.
Table 2. Included Study Characteristics and Results
Table 3. Additional study characteristics
Literature findings
Weight change
There were convergent results across six studies reporting significant weight reduction with GLP-1RA treatment in persons with PDWG. Patients administered GLP-1RAs experienced average weight losses ranging from 3.0 to 5.3 kg, highlighting the potential of these agents to counteract the weight gain typically induced by antipsychotic medicationsReference McElroy and Keck6, Reference Siskind, Russell and Gamble19–Reference Whicher, Price and Phiri22. Wang et al. (2023) reported that participants administered subcutaneous exenatide reported an overall mean change in body weight of −5.29 kgReference Wang, Wang and Yang16. In addition, the mean weight loss of participants taking subcutaneous liraglutide was found to be 5.3 kg more than those in the placebo groupReference Larsen, Vedtofte and Jakobsen20. Similarly, McElroy et al. (2024) reported that persons administered subcutaneous liraglutide demonstrated a −3.7 kg mean change in body weight. Moreover, in a separate study by Whicher et al. (2021), it was observed that 53% of participants administered liraglutide experienced an overall weight change of ≥ 5% (p = 0.015).
In addition, notable improvements in metabolic parameters, such as fasting plasma glucose levels dropping by up to 1.2 mmol/L and HbA1c decreasing by approximately 0.6% was reported in studies focused on prediabetic personsReference Ishøy, Knop and Broberg17, Reference Larsen, Vedtofte and Jakobsen20. More specifically, these metabolic benefits are especially critical for patients at an increased risk of diabetes and cardiovascular diseases. Only one study reported a post-intervention follow-up period of the weight effect over a 12-month period upon completion of the trialReference Siskind, Russell and Gamble19. The other studies did not include the post-intervention follow-up periods so we are unable to conclude on the sustained effects of GLP-1 use on weight on PDWG.
Comparison of exenatide and liraglutide in treating PDWG
All studies reported on the effects of exenatide or liraglutide on PDWG, and both have demonstrated significant efficacy in promoting weight loss. However, their effectiveness and application vary across different populations, presenting distinct clinical implications. The specific evaluation of the use of exenatide in obese adults with schizophrenia treated with olanzapine and/or clozapine found an average weight loss of 5.29 kg, significantly more than the 1.12 kg loss in the usual care groupReference Siskind, Russell and Gamble19. This is a substantial reduction in BMI by 1.78 kg/m² and improvements in fasting glucose levels and HbA1c. These findings underscore exenatide’s specific utility in mitigating the challenging metabolic side effects of antipsychotic medications in patients with schizophrenia who are treated with olanzapine and/or clozapine.
In contrast, investigations of daily liraglutide 3.0 mg in a broader population of overweight and obese individuals demonstrated a higher average weight loss of around 8–10% of initial body weightReference Whicher, Price and Phiri22. Liraglutide demonstrated sustained efficacy over 6 months, with significant reductions in BMI and improvements in lipid profiles, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides, while increasing high-density lipoprotein (HDL) cholesterol levels. This broader applicability suggests liraglutide may offer more pronounced weight reduction benefits compared to exenatide, particularly in patients with generalized obesity and associated cardiovascular risks. For instance, an obese patient without psychiatric comorbidities but with a high cardiovascular risk profile might find liraglutide’s comprehensive metabolic benefits more advantageous.
Effect on metabolic parameters
In addition to mitigating and weight-lowering effects of GLP-1 RAs, beneficial effects on metabolic parameters have also been reported. For example, a mean reduction of 3.2 cm in waist circumference and a reduction in BMI of 1.4 kg/m² was reported in one of the included studies. Improvements in lipid profiles were also noted, with reductions in total cholesterol, LDL cholesterol, and triglycerides, alongside increases in HDL cholesterol levels. Specifically, a reduction in total cholesterol by 0.5 mmol/L, LDL cholesterol by 0.4 mmol/L, and triglycerides by 0.6 mmol/L, coupled with an HDL increase of 0.3 mmol/LReference Larsen, Vedtofte and Jakobsen20. All studies demonstrated similar findings, showing comparable lipid profile improvements, thus suggesting that GLP-1RAs facilitate weight loss and contribute to broader cardiovascular health, which is particularly relevant for patients susceptible to metabolic syndrome. These findings are in accordance with the studies conducted in nonpsychiatric populations, for example, non-insulin-dependent DM.
Safety and tolerability
Gastrointestinal symptoms such as nausea, vomiting, and diarrhea were the most common adverse events, generally mild to moderate in severity and diminishing over timeReference Whicher, Price and Phiri22. Importantly, no severe adverse events were linked to GLP-1RAs, and the dropout rates were similar between the treatment and placebo groups (see Table 3). In addition to the aforementioned treatment-emergent profile, there is no evidence that GLP-1RAs engender or amplify any dimension of psychopathology. Reports of suicidality associated with GLP-1RAs have been thoroughly evaluated, and no cause and effect has been establishedReference Wang, Wang and Yang16, Reference McIntyre24. In addition, preliminary findings suggest that GLP-1RAs may prevent and treat aspects of psychopathology, including cognitive impairment and mood-related symptomsReference Meissner, Remy, Giordana and Maltête25, Reference Cukierman-Yaffe, Gerstein and Colhoun26, Reference Cooper, Ramachandra and Ceban27.
Discussion
Taken together, the results of our analysis indicate that GLP-1RAs can meaningfully improve anthropometric and metabolic measures in persons experiencing PDWG. The outcome measures of interest are replicated, robust, and clinically meaningful, providing preliminary empirical support for these agents in the treatment and prevention of PDWG. Persons with mental disorders are differentially affected by obesity and metabolic comorbidity, which would provide separate and independent justification for the use of these agentsReference Liu, Ling and Lui3, Reference Jawad, Meshkat and Tabassum4. Considering the heightened risk of obesity and metabolic comorbidities among those with mental disorders, there is a compelling, independent justification for employing these agents where indicated to primarily target obesity and/or comorbid T2DM. Although our primary focus has been on weight gain, a more systematic evaluation of GLP-1RAs would be beneficial, not only concerning body weight but also in addressing related conditions like metabolic syndrome, dyslipidemia, diabetes, nonalcoholic fatty liver disease, and cardiovascular disease. This broader perspective could provide a more comprehensive understanding of the therapeutic potential of GLP-1RAs.
The results of our analysis need to be interpreted with several limitations with respect to the methodology and extant literature. First, it is important to note that although the data generally suggest that the use of GLP-1RAs is beneficial in mitigating PDWG, the current data are mixed, and a portion of the studies are not placebo-controlled. Overall, three of the reviewed studies where patients were blinded to their treatment and one study without blinding showed a benefit of using GLP-1RAs to mitigate PDWGReference Siskind, Russell and Gamble19–Reference Whicher, Price and Phiri22. Conversely, two studies reported no significant benefit of using GLP-1RAs for body weight reductionReference Ishøy, Knop and Broberg17, Reference Maagensen, Larsen, Jørgensen, Fink-Jensen and Vilsbøll18. Additionally, significant heterogeneity across the studies concerning patient demographics, illness characteristics, comorbidities, and treatment regimens presents a challenge. For instance, variations in baseline anthropometric and metabolic status and the presence of other health conditions could have influenced the outcomes, affecting the generalizability of the findings. The psychotropic medications prescribed in the extant studies included were also not uniform and the results reported may not apply to other psychotropic regimens. Moreover, within class (eg, antipsychotics), there is a gradient of liability for weight change; hence, no statements regarding specific mitigating capability can be made with GLP-1RAs for any particular agent. Additionally, the duration of the studies varied considerably, with some extending several months in duration, limiting the observation of long-term effects and potential side effects of GLP-1RAs. Only one study had a post-intervention follow-up, which allows the observation of the sustained effect of GLP-1Reference Siskind, Russell and Gamble19. Another critical limitation is the diversity in the types of GLP-1RAs used and the dosages administered, which may affect both efficacy and safety findings with GLP-1RAs in the psychiatric population.
Although the studies generally reported favorable tolerability profiles for GLP-1RAs, they primarily focused on short-term adverse events, such as gastrointestinal symptoms, with inadequate characterization of long-term tolerability. Although reports appear of an association between GLP-1RAs and suicidality, reports from the US FDA and European Medicines Agency have concluded that no causality existsReference McIntyre10, 28, 29.
With respect to clinical translation, an initial strategy for a person experiencing PDWG for consideration would be switching to medications with a lower propensity for weight gain. In addition to behavioral modification and dietary change, the use of adjunctive metformin can be considered. Evidence indicates that metformin has a larger effect size for weight mitigation when used in a primary prevention paradigm when compared to a secondary prevention paradigmReference McIntyre, Kwan, Rosenblat, Teopiz and Mansur1. GLP-1RAs should be considered in any person wherein the use would be indicated insofar as they have obesity and/or T2DM. More narrowly, GLP-1RAs could also be considered as potential treatment avenues in persons experiencing PDWG. It is separately noted that GLP-1RAs benefit other comorbidities known to differentially affect persons with serious mental illness (eg, cardiovascular disease, metabolic dysfunction associated with steatotic liver disease)Reference McIntyre, Kwan, Rosenblat, Teopiz and Mansur1. Future research vistas include but are not limited to ascertaining whether GLP-1RAs also benefit dimensions of psychopathology, including cognitive impairment, reward behaviour and mood dysregulationReference Cooper, Ramachandra and Ceban27, Reference McIntyre, Mansur, Rosenblat and Kwan30.
Conclusion
Our results indicate that substantial and clinically meaningful effects of GLP-1RAs on weight and associated metabolic parameters is observed in persons with mental disorders receiving these agents either specifically to mitigate PDWG and/or contemporaneous therapeutic targeting of obesity as well as metabolic parameters. In addition to their benefit across weight and metabolic parameters, these agents are well-tolerated and safe with no identified serious safety concerns. Future research vistas include adequate well-controlled studies with GLP-1RAs in psychiatric populations evaluating obesity, metabolic and safety outcomes (e.g., suicidality)Reference McIntyre, Mansur and Rosenblat31, Reference McIntyre24.
Author contribution
Writing – review & editing: B.C., M.V., A.K., G.H.L., K.T., K.V., S.L., K.G.L., H.K.L., R.H., S.W., T.G.R., T.M., X.Y.G., Y.J.Z., R.S.M.; Conceptualization: S.L., R.S.M.; Formal analysis: S.L., H.K.L., T.M., X.Y.G., R.S.M.; Investigation: S.L., T.M., X.Y.G., R.S.M.; Methodology: S.L., R.S.M.; Visualization: S.L., H.K.L., T.M., X.Y.G., R.S.M.; Writing – original draft: S.L., T.M., X.Y.G., R.S.M.
Competing interest
Roger S. McIntyre has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, Atai Life Sciences. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp.
Kayla M. Teopiz has received fees from Braxia Scientific Corp.
